As the incidence of cystic fibrosis (CF) bone disease is increasing, we analyzed CF transmembrane conductance regulator (CFTR) deficient mice (CF mice) to gain pathogenic insights. In these studies comparing adult (14 wk) CF and C57BL/6J mice, both bone length and total area were decreased in CF mice. Metaphyseal trabecular and cortical density were also decreased, as well as diaphyseal cortical and total density. Trabecular bone volume was diminished in CF mice. Female CF mice revealed decreased trabecular width and number compared with C57BL/6J, whereas males demonstrated no difference in trabecular number. Female CF mice had reduced mineralizing surface and bone formation rates. Conversely, male CF mice had increased mineralizing surface, mineral apposition, and bone formation rates compared with C57BL/6J males. Bone formation rate was greater in males compared with female CF mice. Smaller bones with decreased density in CF, despite absent differences in osteoblast and osteoclast surfaces, suggest CF transmembrane conductance regulator influences bone cell activity rather than number. Differences in bone formation rate in CF mice are suggestive of inadequate bone formation in females but increased bone formation in males. This proanabolic observation in male CF mice is consistent with other clinical sex differences in CF. 
C ystic fibrosis (CF) is a relatively common single gene disorder characterized by chloride channel dysfunction in multiple organ systems, several of which contribute to a systemic inflammatory state in most patients (1, 2) . In Caucasians, it is the leading life-limiting recessive genetic disorder and originates from a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene (3) . The first clinical manifestations may occur during the fetal period, with intestinal obstruction and perforation of the bowel. However, the major manifestations that afflict these individuals include the inability to absorb fats and other nutrients from the intestine, as well as poor lung function secondary to airway inflammation and infection. Other problems associated with CF include diabetes, bone mineral disease, poor growth, liver disease, infertility, and chronic sinusitis. In 1938, the mean life expectancy for children with CF was less than 1 y (4). Over the past 30 y, the life expectancy of children with CF in the United States has increased from 16 y of age to 37 y (2,4). This change has been attributed to improvements in airway clearance, antibiotics, and nutritional support.
As life expectancy of CF patients has increased, chronic complications of the disorder have become more prominent. Bone disease is a major impediment to the quality of life and overall health of adolescents and young adults with CF (5) . The frequency of bone disease in CF has increased to 16.7% of the nearly 25,000 patients currently enrolled in the CF Foundation Patient Registry (2). Currently, the CF Foundation recommends that all patients above the age of 18 y be screened for osteoporosis (6, 7) . Although controversy exists over whether fractures are increased in individuals with CF, case reports of severe outcomes persist (5, 8, 9) . In one extreme case, Latzin et al. (10) describe a 16-y-old girl with CF and osteoporosis, who died from respiratory failure after a spontaneous fracture of the midsternum.
However, the full impact of decreased bone mineral density (BMD) and its pathogenesis in CF are not known. Many factors weigh against the development of normal bone health in individuals with CF. Some problems develop during the childhood years of a patient with CF, including poor nutrition, malabsorption of vitamin D, poor growth, and delayed pubertal development (7) . Malabsorption of fats and proteins secondary to pancreatic insufficiency is reported in 59% of newborns with CF and by 1 y of life, 90% are affected (4). The resultant inability to absorb fat-soluble vitamins, most importantly vitamin D, but also vitamin K, is linked to abnormalities in bone mineral metabolism (11, 12) . Problems with malabsorption inherently result in poor growth, although in the presence of adequate nutrition via gastrostomy feedings, growth may still be impaired (13) . Other contributors to bone disease that tend to occur as individuals age include chronic pulmonary infections, decreased physical activity, hypogonadism, and corticosteroid usage (6,7).
Elkin et al. (14) illustrate complexities of CF bone disease with a comparison of bone formation rates in CF individuals versus controls. Although demonstrating a reduction in bone formation rate in CF subjects, the study was confounded by pancreatic insufficiency, ongoing lung disease, and chronic corticosteroid therapy. Corticosteroids interfere with bone formation and increase bone resorption (15, 16) . Use of animal models such as CFTR-deficient mice allows investigators to separate out variables.
Our hypothesis is that an inherent dysfunction of bone mineral metabolism is directly associated with CFTR dysfunction in CF, and subsequently the loss of normal function will result in decreased bone density in the murine model. Previous studies using CFTR-deficient mice without gut correction described decreased bone density without evidence of sexrelated differences (17) (18) (19) . To our knowledge, this is the first and most comprehensive analysis of bone in gut-corrected CF mice, including dynamic evidence of differences in bone formation between sexes.
METHODS

Mice.
The primary CFTR knockout strain used in this study was the Cftr S489ϫϪ/Ϫ neo insertion in C57BL/6J mice, initially developed at the University of North Carolina and then modified with the transgenic overexpression of gut-specific human CFTR from the fatty acid binding promoter to prevent intestinal obstruction, allowing for weaning to a normal solid chow diet, and overall improving viability. C57BL6 Cftr(Ϫ/Ϫ) fatty acid binding promoter-hCftr(ϩ/ϩ) have been back crossed against the C57BL/6J mouse for greater than 10 generations, providing a knockout comparison with the C57BL/6J mouse. Mice are bred via heterozygote breeding pairs and housed under specific pathogen-free conditions at the University of Florida Animal Care Services according to National Institutes of Health guidelines and allowed food and water ad libitum. All experimental procedures were approved by University of Florida IACUC.
Prenecropsy and necropsy procedures. All mice were injected s.c. with the fluorochrome compounds declomycin and calcein at a dose of 15 mg/kg body weight on the 5th and 2nd day before killing, respectively (20) . Ten CF mice (five male and five female) and 14 C57BL/6J mice (five male and nine female) were killed at 14 wk of age. After killing, both femora from each animal were stripped of musculature and placed in 10% phosphate-buffered formalin (pH 7.4) for 24 h for tissue fixation. These bone specimens were then transferred to 70% ethanol and processed as described below.
Ex vivo bone structural analyses. The length of the left femur was measured in each animal with a precision caliper (General Hardware, New York, NY), after which these long bones were scanned by peripheral quantitative computed tomography (pQCT) with a Stratec XCT Research M instrument (Norland Medical Systems, Fort Atkinson, WI). Scans were performed at distances of 2.5 and 7.5 mm proximal to the distal end of the femur for measurements of cancellous and cortical bone structure, respectively. The first site (2.5 mm) was at the level of the secondary spongiosa of the distal femoral metaphysis, whereas the second site (7.5 mm) was in the femoral diaphysis composed entirely of cortical bone. The structural variables that were measured include total mineral content, trabecular content, cortical content, total mineral density, trabecular density, cortical density, total area, trabecular area, cortical area, marrow area, cortical thickness, and periosteal circumference.
Quantitative bone histomorphometry. The right distal femur from each animal was dehydrated in increasing concentrations of ethanol and embedded undecalcified in modified methyl methacrylate (21) . The embedded bones were sectioned longitudinally at 4 and 8 m thickness with Leica/Jung 2050 or 2165 microtomes. The 4-m thick sections were stained according to the Von Kossa method with a tetrachrome counterstain. Structural and cellular variables were measured in these sections with the Osteometrics System (Atlanta, GA) and the Bioquant Elite Bone Morphometry System (R&M Biometrics, Nashville, TN). The sample area within the distal femoral metaphysis began at 1 mm proximal to the growth plate to exclude the primary spongiosa. The following bone variables were measured in the thin sections: cancellous bone volume (%), trabecular number (#/mm), trabecular separation (m), trabecular width (m), osteoblast surface (%), and osteoclast surface (%). In addition, the following fluorochrome-based data were collected from unstained, 8-m thick bone sections with the same quantitative system: mineralizing surface (%), mineral apposition rate (m/d), and bone formation rate (surface referent, m 3 /m 2 /d). Statistical analysis. Data were analyzed via an unpaired t test. Results are reported as mean values with SD. All statistical analyses were conducted using GraphPad Prism 5.0 software with a two-tailed p Ͻ 0.05 considered significant (GraphPad Software, San Diego, CA).
RESULTS
Cftr؊/؊ genotype results in decreased femur size. Femur size of C57BL/6J and CF mice was compared (Table 1) based on femur length (measured by precision calipers) and area (obtained by pQCT). Femur length was shorter in both male and female CF mice compared with gender-matched C57BL/6J controls (males p Ͻ 0.001 and females p Ͻ 0.0001). Metaphyseal total area was reduced in both male and female CF mice (p Ͻ 0.001 for both), as well as total area of diaphysis (p Ͻ 0.01 and p Ͻ 0.001, respectively). In addition, cortical bone area was reduced in both male and female CF mice at both the metaphysis and diaphysis (metaphysis: male p Ͻ 0.001 and female p Ͻ 0.0001; diaphysis: male p Ͻ 0.01 and female p Ͻ 0.0001).
CF mice have decreased bone content and density. Bone content and density were compared by pQCT (Table 2 and Fig. 1 ) at both the metaphysis and diaphysis in male and female CF mice and C57BL/6J controls. At the metaphysis, CF mice have decreased total bone content and density (bone content: males p Ͻ 0.001 and females p Ͻ 0.0001; bone density: males p Ͻ 0.01 and females p Ͻ 0.001). Trabecular bone content and density were reduced in CF mice (bone content: males p Ͻ 0.01 and females p Ͻ 0.001; bone density: males p Ͻ 0.05 and females p Ͻ 0.01). In addition, cortical bone content and density were reduced in CF mice compared with C57BL/6J controls (bone content: males p Ͻ 0.01 and females p Ͻ 0.0001; bone density: males p Ͻ 0.05 and females p Ͻ 0.0001).
Total bone content and density were reduced in CF mice compared with C57BL/6J mice at the diaphysis (bone content: (Table 3) Table 3 . Figure 2 shows representative distal femurs from C57BL/6J and CF mice. Table 3 details the mean values and SD of the dynamic bone measurements. Percentage of mineralizing surface was reduced in female CF mice (p Ͻ 0.0001) but increased in male CF mice (p Ͻ 0.001). In addition, mineral apposition rate was increased in male CF mice (p Ͻ 0.05) and approached a significant decrease in female CF mice (p ϭ 0.09). The calculated bone formation rate was decreased in CF female mice compared with controls (p Ͻ 0.0001) and increased in CF male mice compared with male controls (p Ͻ 0.01) and female CF mice (p Ͻ 0.05) (Fig. 3) .
DISCUSSION
The incidence of CF bone disease continues to rise as the mean life expectancy of CF patients continues to increase (2,5,6). The origin of osteoporosis is postulated to be multifactoral in healthy individuals. In CF, factors associated with bone disease seem to be intensified. The contribution of the CF genetic background has only recently arrived on the scene of mechanisms of disease. Our novel findings not only demonstrate decreased bone density in adult CF mice but also report sex-related differences in bone metabolism. Our model is based on CFTR deficient mice with a transgenic human gut correction. The advantage of this model is that it improves viability and life expectancy of the mice, and eliminates concerns for gut absorption and nutritional deficiency.
For many years, increased corticosteroid usage was blamed for decreased bone density in CF. Corticosteroids interfere with calcium absorption from the gut, decrease renal tubular reabsorption of calcium, suppress osteoblastic formation of new bone, and decreasing gonadal hormone production (15) . Regarding bone resorption, corticosteroids increase osteoclastogenesis via increased production of receptor activator of nuclear factor-kappa B ligand (16) . Stimulation of the receptor activator of nuclear factor-kappa B results in osteoclastogenesis. Aris et al. (22) described increased markers of bone turnover in CF, reporting elevated urinary N-telopeptides and serum bone-specific alkaline phosphatase in CF subjects compared with healthy age-matched controls.
New insights into the development of osteoporosis implicate the impact of chronic systemic inflammation on the loss of bone mass (23) . Inflammatory influences may originate in the bone marrow, peripheral blood, or directly at the bone. Reports suggest that proinflammatory cytokines and other biochemical signals are driving osteoclastogenesis in CF. The most common CFTR mutation ([Delta]F508) is a missense mutation which produces a misfolded version of CFTR that has been shown to trigger an endoplasmic reticulum overload response within cells (24) , resulting in widespread changes in gene expression (25) (26) (27) (28) . Among the most prominent of these changes is an up-regulation of proinflammatory cytokines associated with innate immunity (26) . This may correlate with the observation that CF patients (29) and CF mice (30) show an exaggerated proinflammatory cytokine response to bacterial challenge, when compared with normal individuals or control mouse strains. This same up-regulation of proinflammatory cytokines may be driving the delineation of osteoclast formation and subsequent bone loss. A study on the impact of inflammation on bone mineral content in CF by Haworth et al. (31) reported increased levels of urinary markers for osteoclast activity related to serum levels of IL-6. Shead et al. (23) detected increased levels of osteoclast precursors in CF patients during infective exacerbations, specifically
In an earlier study, Haworth et al. (32) demonstrated decreased osteoblastic and increased osteoclastic activity via bone histomorphology in adult CF patients. Whereas the reduced osteoblastic activity was the result of both decreased osteoblast numbers and diminished action via osteoid production, larger osteoclast numbers, and evidence of increased absorption determined greater osteoclastic activity. In our study, we observed no difference in osteoclast surfaces in CF mice of both genders. Our findings suggest that an increase in bone resorption in these animals is due to an increase in osteoclast activity rather Histomorphological comparison of distal femurs from 14-wk-old C57BL/6J CftrϪ/Ϫ to C57BL/6J mice. C57BL/6J CftrϪ/Ϫ animals exhibited decreased indices of cancellous bone mass, which were more pronounced in female mice. No significant differences were observed in % osteoblast and osteoclast surfaces. Dynamic indices of bone formation demonstrate decreased bone formation rate (BFR) in females but increased BFR in male C57BL/6J CftrϪ/Ϫ mice. BFR was greater in male compared with female C57BL/6J CftrϪ/Ϫ mice (p Ͻ 0.5, see Fig. 3) .
p values for comparison with same-sex C57BL/6J mice: * p Ͻ 0.01, † p Ͻ 0.05, ‡ p Ͻ 0.0001, and § p Ͻ 0.001.
than an increase in osteoclast numbers. Although this differs slightly from the findings previously described in humans, further investigations to induce inflammation in this mouse model will help delineate the relationship. Despite strong evidence of systemic modulators, we must not overlook the potential impact of CFTR itself on bone formation. Originally described in 2004 by Dif et al. (17) , 3-wk-old CFTR-deficient mice demonstrated reduced bone density and bone formation compared with heterozygote (CftrϪ/ϩ) and wild-type (Cftrϩ/ϩ) controls. The CFTRdeficient mouse model used by Dif et al. typically succumbs to intestinal obstruction when weaned to a solid chow diet. Thus, mice were compared before weaning and using only female mice controlled for gender differences. Evidence further surfaced on the significance of CFTR in bone metabolism when Shead et al. (33) demonstrated expression of CFTR in human osteoblasts, osteocytes, and osteoclasts. However, as with other tissues in the body, CFTR expression does not necessarily translate to function. Two recent studies have described decreased bone density persisting into adulthood in CFTR-deficient mice (18, 19) . Both studies used CFTR-deficient mice without gut correction and required supplemented feeds. Haston et al. (19) described reduced bone density in both 12 and 28-wk CFTR-deficient mice but found no difference in male or female mice. Our model for bone disease in CF requires no additional nutritional supplementation to prevent intestinal obstruction, eliminating influences of medical intervention, and improving the overall nutritional patency of the animal.
In addition to the direct contribution of CFTR on bone metabolism, which is suggested by protein expression, indirectly the production of anabolic hormones involved in bone remodeling must be considered. Although normal growth hormone values are reported in patients with CF, decreased levels of the downstream product IGF-I are described (34) . Both are involved with bone metabolism and growth. IGF-I, a nutritionally dependent, growth hormone driven regulator of bone growth, is decreased in children with CF, even with gastrostomy nutritional supplementation (13) . Furthermore, Rosenberg et al. (35) detailed decreased concentrations of IGF-I and liver IGF-I mRNA in both male and female CFTRdeficient mice.
Gut correction of CF mice used in our study, although allowing a normal diet, does not improve growth. Rosenberg et al. (35) demonstrated growth impairment (weight and length) in CFTR-deficient mice. To control for size differences, we used pQCT to analyze bone sections. Size artificially increases measured BMD in a two-dimensional analysis by dual-energy x-ray absorptiometry that measures areal BMD in g/cm 2 . pQCT eliminates these artifacts and measures a volumetric BMD (g/cm 3 ). Bones of different sizes, from individuals of variable weight, can be compared (36) .
However, pQCT does not remove differences in pubertal status. Previous studies in CFTR-deficient mice examined animals at 3 wk (prepubertal) and also attempted to evaluate mice at the pubertal age of 8 wk (17, 19) . Comparison of 8-wk-old CFTR-deficient mice is problematic because of differences in pubertal progression. Puberty (determined by vaginal opening) is delayed up to 4 wk in CF mice (37) . In a study by Jin et al., puberty occurred at 31.3 Ϯ 1.4 d for wild-type female mice versus 48.9 Ϯ 9.3 d for CFTR-deficient females. To further eliminate variables in our study, BMD was only compared in mice of the same sex. Comparisons between male and female mice were made by bone formation rates, calculated from histomorphometry.
Interestingly, we found increased bone formation in male CF mice compared with females. This reflects general clinical differences in disease phenotype of men and women with CF. The concept of sex-related differences in CF are well established. These differences have included a more rapid decline in pulmonary function (38) , alterations in voltage across the nasal epithelium (as measured by nasal potential difference) depending on menstrual cycles (39), colonization with Pseudomonas aeruginosa (40) , and even emotional impact of disease (41) . One of the most prominent differences in males and females with CF occurs with CF-related diabetes. Milla et al. (42) reported a decreased survival in females with CFrelated diabetes by 16.3 y, whereas only 2.1 y for males. The etiology of these differences remains unclear.
Hodges et al. (43) detailed decreased fertility in female CFTR deficient mice. They found reduced uterine and ovarian size, decreased ovulation rates, and abnormalities in estrous cycles. Gonadotropins, follicle stimulating hormone and LH, were within normal range reported for mice. Furthermore, exogenous human chorionic gonadotropin corrected differences in organ size and ovulation of CFTR deficient mice. This suggests hypothalamic hypogonadism, a central dysfunction of sex hormone production. Similar findings occur in women with CF, including a delay in puberty and abnormalities in hormone production suggestive of hypothalamic origins (44 -47) . Amenorrhea, anovulation, irregular cycles, smaller uteri, and decreased estrogen levels are associated with CF women (45, 48) . Moreover, estrogen is a major contributor to bone health, growth, and remodeling. The effects are primarily proosteoblastic and antiosteoclastic through both direct and indirect signaling (49) .
The increased rate of bone formation in male CF mice would lead one to expect a greater bone density in male CF mice compared with controls. However, bone density is determined by the equilibrium (or lack of equilibrium) between bone formation and bone resorption (6, 22, 49) . Increased bone formation, coupled with a reduced bone density, suggests bone loss through increased bone resorption. Additional studies of osteoclast dynamics, and markers of bone breakdown, are needed to fully detail bone resorption in these animals. It is this inequality of reduced bone formation and increased bone resorption that we propose leads to the resultant state of osteopenia in CF.
In summary, CF-related bone disease is the quintessential multifactoral disease. Data support a genetic susceptibility that combines with an environment rich in modifiers to increase bone resorption and poorly promote bone formation. Gender differences in disease represent magnifications of these modifiers. Improving our understanding of CF-related bone disease has the potential to decrease the incidence, develop better therapies, and advance the overall understanding of mechanisms in metabolic bone disease.
